Zercepac Европейски съюз - полски - EMA (European Medicines Agency)

zercepac

accord healthcare s.l.u. - trastuzumab - breast neoplasms; stomach neoplasms - Środki przeciwnowotworowe - breast cancermetastatic breast cancer zercepac is indicated for the treatment of adult patients with her2 positive metastatic breast cancer (mbc):as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. do chemioterapii powinny być zawarte co najmniej антрациклина i таксана, jeśli pacjenci nie nadają się do tych procedur. hormon-receptor-pozytywnych pacjentów również musi być terapii hormonalnej, jeśli pacjenci nie nadają się do tych procedur.                      in combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable. w połączeniu z docetakselem w leczeniu pacjentów, którzy nie otrzymywali chemioterapii w rozsiana choroba. w połączeniu z inhibitorem aromatazy w leczeniu pacjentów w menopauzie z hormon-receptor pozytywne rozrzadu, nie wcześniej otrzymujących trastuzumab. early breast cancer zercepac is indicated for the treatment of adult patients with her2 positive early breast cancer (ebc). po operacji, chemioterapii (neoadiuwantowej lub uzupełniające) i radioterapii (jeśli dotyczy). po chemioterapii adjuwantowej z doksorubicyną i cyklofosfamidem, w połączeniu z mzios lub docetaxel. w połączeniu z adjuwantowej chemioterapii składającej się z docetaksela i carboplatina. in combination with neoadjuvant chemotherapy followed by adjuvant zercepac therapy, for locally advanced (including inflammatory) disease or tumours > 2 cm in diameter. zercepac should only be used in patients with metastatic or early breast cancer whose tumours have either her2 overexpression or her2 gene amplification as determined by an accurate and validated assay. metastatic gastric cancer zercepac in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with her2 positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction who have not received prior anti-cancer treatment for their metastatic disease. zercepac should only be used in patients with metastatic gastric cancer (mgc) whose tumours have her2 overexpression as defined by ihc2+ and a confirmatory sish or fish result, or by an ihc 3+ result. należy użyć dokładne i sprawdzone metody analizy .

Palforzia Европейски съюз - полски - EMA (European Medicines Agency)

palforzia

aimmune therapeutics ireland limited - defatted powder of arachis hypogaea l., semen (peanuts) - peanut hypersensitivity - allergens - palforzia is indicated for the treatment of patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy. palforzia may be continued in patients 18 years of age and older. palforzia should be used in conjunction with a peanut-avoidant diet.

Kesimpta Европейски съюз - полски - EMA (European Medicines Agency)

kesimpta

novartis ireland ltd - ofatumumab - stwardnienie rozsiane, Рецидивно-znika - immunosuppressant - kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features (see section 5.